You are here
The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.
ARGOM: Guidelines on the pre-market application and evaluation process for OTC medicines
Version 1.3, April 2014
This guidance has been updated and this webpage will be archived on 1 March 2016.
Please go to OTC new medicines registration process for the updated guidance which you can commence using.
Australian regulatory guideline for over-the-counter medicines
This interim guideline details the new regulatory processes for the approval of new and changed OTC medicines. The new process is to be implemented in stages.
This guideline describes the process that will apply when fully implemented and is to be read in conjunction with the guidance regarding the implementation stages for the new process.
|Version||Description of change||Author||Effective date|
|V1.0||Update of ARGOM application and evaluation process||OMA - OTCME||15/04/2013|
Improved hyperlinks and information regarding applications for umbrella branded medicines.
Clarified requirement for analytical validation summary forms and included hyperlink.
Clarified the requirements for GMP clearance.
Clarified 'calendar days' through-out and changed from 'working days' to 'calendar days' for ACNM cut-off date.
Highlighted where requirements are subject to staged implementation.
|OMA - OTCME||15/04/2013|
Minor formatting updates
Added hyperlinks to OTC N2 application requirements and OTC Medicine Monographs.
|OMA - OTCME||06/09/2013|
Delete some references to staged implantation.
Update reference to 'other' change codes.
Correction and consolidation of information regarding fees.
Clarified that certification of registration is sent out after receiving the S26B certificate or notification.
|OMA - OTCME||09/04/2014|
© Commonwealth of Australia 2014
This work is copyright. You may download, display, print and reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted under the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to <firstname.lastname@example.org>.